News Sentiment

RLYB sentiment intelligence

Rallybio Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.73 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

74/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-0.5% over one week, -1.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Rallybio Corporation (NASDAQ: RLYB) to merge and rebrand as Avenzo Therapeutics

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 74/100 classification
One-week reaction -0.5% Price digesting
Trend fit Trend active -1.2% over four weeks
Fair value 29.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 32
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Market source 7
TradingView 4
Investing.com 4
TradingKey 3
Business Wire 2
Quiver Quantitative 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Deals and strategy 20
Market update 17
Earnings 12
Regulatory and legal 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Stock Titan Direct company coverage

Rallybio Corp (RLYB) director exercises stock options, lifts stake to 6,542 shares

Rallybio Corp director Helen M. Boudreau exercised options to acquire 3,562 shares of Common Stock on July 6, 2026, at an exercise price of $2.38 per share. This transaction increased her direct holdings to 6,542 shares. The exercised options were "Right to Buy" with an expiratio

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 20:39
Source
Stock Titan
TradingKey Direct company coverage

Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Rallybio Corp (RLYB) has an earnings forecast score of 6.00, placing it 333rd out of 389 in the Biotechnology & Medical Research industry. Analysts have a consensus price target of $1.00 for RLYB, with one analyst currently holding a "Hold" rating for the stock. The company's EPS

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 00:39
Source
TradingKey
TradingKey Direct company coverage

Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Rallybio Corp (RLYB), focusing on business segments, regional revenue, and profit contribution. It notes that relevant data for FY2025 and FY2024 has not yet been disclosed by the company, though it does show a United States revenue o

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 22:10
Source
TradingKey
TradingKey Direct company coverage

Rallybio Corp (RLYB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Rallybio Corp (RLYB). It states that Rallybio Corp has distributed no dividends over the past five years and lists one upcoming stock split event: a merger with an 8-to-1 ratio scheduled for January 29, 2026.

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 21:10
Source
TradingKey
Mondaq Direct company coverage

United States - Mintz Advising On $215 Million Private Placement Concurrent With Avenzo Therapeutics’ And Rallybio’s Merger Transaction

Mintz is advising the placement agents for a $215 million private placement that will close concurrently with the merger transaction between Avenzo Therapeutics, Inc. and Rallybio Corporation. The Mintz team, including capital markets, regulatory, and intellectual property adviso

Tone
Positive 72/100
Event
Deals and strategy
Published
08 Jun 2026 15:39
Source
Mondaq
Stock Titan Direct company coverage

ADAR1, Daniel Schneeberger disclose 17.5% stake in Rallybio (RLYB)

ADAR1 Capital Management, LLC and Daniel Schneeberger have disclosed a 17.5% stake in Rallybio (RLYB), owning 926,352 shares through private funds and separately managed accounts. This disclosure was made via a Schedule 13G filing, indicating a passive investment intent. Daniel S

Tone
Neutral 50/100
Event
Deals and strategy
Published
05 Jun 2026 20:39
Source
Stock Titan
Investing.com Direct company coverage

Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock

ADAR1 Capital Management, LLC and Daniel Schneeberger collectively purchased approximately $2.18 million worth of Rallybio Corp (NASDAQ:RLYB) common stock on May 4 and 5, 2026. This insider buying activity occurs as RLYB trades near its 52-week high after a 505% gain over the pas

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 03:09
Source
Investing.com
Business Wire Direct company coverage

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Kahn Swick & Foti, LLC (KSF) is investigating the proposed merger of Rallybio Corporation (RLYB) and Avenzo Therapeutics, Inc., following which current Rallybio equityholders are expected to own approximately 2.8% of the combined company. KSF aims to determine if the merger and i

Tone
Negative 36/100
Event
Deals and strategy
Published
03 Jun 2026 07:40
Source
Business Wire
PR Newswire Direct company coverage

Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Rallybio (Nasdaq: RLY) regarding its recently announced transaction with Avenzo Therapeutics, citing potential breaches of fiduciary duty and other legal violations. Rallybio equityholders are expected to own only 2.8% of the combined company, while Ave

Tone
Negative 28/100
Event
Market update
Published
02 Jun 2026 16:14
Source
PR Newswire
GlobeNewswire Direct company coverage

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of

Brodsky & Smith LLC is investigating several companies, including Taylor Morrison Home Corporation, Rallybio Corporation, InMed Pharmaceuticals, Inc., and KalVista Pharmaceuticals, Inc., for potential breaches of fiduciary duties. The investigations focus on whether the proposed

Tone
Negative 38/100
Event
Regulatory and legal
Published
02 Jun 2026 15:51
Source
GlobeNewswire
Stocktwits Direct company coverage

RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?

Rallybio (RLYB) shares surged over 20% to a two-year high after announcing a merger agreement with Avenzo Therapeutics. The combined entity, which will operate as Avenzo Therapeutics and trade under AVZO, will focus on oncology and has secured $215 million in financing. Existing

Tone
Neutral 50/100
Event
Deals and strategy
Published
02 Jun 2026 11:40
Source
Stocktwits
Yahoo! Finance Canada Direct company coverage

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

Rallybio Corporation and Avenzo Therapeutics have announced a merger agreement to advance next-generation oncology therapies, with the combined company to operate as Avenzo Therapeutics. Avenzo also secured a $215 million oversubscribed private placement financing, expected to fu

Tone
Positive 64/100
Event
Deals and strategy
Published
02 Jun 2026 07:10
Source
Yahoo! Finance Canada
TradingView Direct company coverage

Rallybio to Merge With Avenzo in Stock Deal; $215 Million Financing Planned

Rallybio (RLYB) announced a stock-for-stock merger agreement with Avenzo Therapeutics, which will result in a rebrand to Avenzo Therapeutics and a $215 million private placement. This financing is a closing condition and will fund the combined company, with pro forma ownership si

Tone
Positive 77/100
Event
Deals and strategy
Published
02 Jun 2026 05:40
Source
TradingView
Stock Titan Direct company coverage

Cancer drug startup Avenzo gets $215M as it goes public via Rallybio merger

Rallybio Corporation and Avenzo Therapeutics have announced a merger agreement, under which Avenzo will go public and receive $215 million in a private placement. The combined company will operate as Avenzo Therapeutics, focusing on next-generation oncology therapies, including s

Tone
Positive 66/100
Event
Deals and strategy
Published
01 Jun 2026 17:11
Source
Stock Titan
TradingView Direct company coverage

Rallybio amends employment and separation agreements for Stephen Uden, Jonathan Lieber and Steven Ryder

Rallybio (RLYB) has amended the employment agreements for Stephen Uden and Jonathan Lieber, and a separation agreement for Steven Ryder. These amendments specify that the upcoming Merger will be considered a change in control. This change ensures that the individuals are eligible

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jun 2026 12:39
Source
TradingView
Stock Titan Direct company coverage

Rallybio (NASDAQ: RLYB) to merge into Avenzo Therapeutics with $215M private financing and CVRs

Rallybio (NASDAQ: RLYB) announced a definitive merger agreement with Avenzo Therapeutics, a clinical-stage biotechnology company. The transaction involves Rallybio acquiring Avenzo in an all-stock reverse-triangular merger, coupled with a concurrent oversubscribed private placeme

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Jun 2026 11:39
Source
Stock Titan
Finviz Direct company coverage

RLYB - Rallybio Corp Stock Price and Quote

Rallybio Corp (RLYB) closed at $15.94, showing a slight increase of 0.19%. The company, which specializes in biotechnology products for rare diseases, has a market cap of $84.45M and a significant insider ownership of 34.53%. Recent news includes merger agreements with Avenzo The

Tone
Positive 65/100
Event
Deals and strategy
Published
28 May 2026 08:39
Source
Finviz
Benzinga Direct company coverage

Rallybio Analyst Ratings and Price Targets | NASDAQ:RLYB

Rallybio Corp (NASDAQ:RLYB) has a consensus price target of $8.88 from 7 analysts, with a high of $15 and a low of $1.50. Recent analyst ratings indicate a potential downside, with HC Wainwright & Co. setting an average price target of $5. The article also details recent downgrad

Tone
Negative 14/100
Event
Analyst action
Published
28 May 2026 03:39
Source
Benzinga
Simply Wall Street Direct company coverage

Rallybio (Nasdaq:RLYB) - Stock Analysis

Rallybio Corporation (RLYB) is a clinical-stage biotechnology company developing therapies for rare diseases. The company faces significant financial risks, including low revenue, unprofitability, and high stock price volatility, alongside concerns about its cash runway. Recently

Tone
Negative 34/100
Event
Earnings
Published
24 May 2026 13:10
Source
Simply Wall Street
Investing.com India Direct company coverage

Adar1 Capital Management, Daniel Schneeberger buy $226k Rallybio stock

ADAR1 Capital Management and its manager, Daniel Schneeberger, collectively purchased approximately $226,563 worth of Rallybio Corp (NASDAQ:RLYB) common stock across two days in May 2026. These insider transactions involved 16,209 shares, acquired at prices ranging from $13.80 to

Tone
Neutral 50/100
Event
Market update
Published
21 May 2026 12:39
Source
Investing.com India
Stock Titan Direct company coverage

ADAR1-managed funds boost Rallybio (RLYB) stake with open-market share buys

ADAR1 Capital Management, LLC, through its managed funds and accounts, increased its stake in Rallybio Corp (RLYB) by purchasing 16,209 shares in open-market transactions on May 18-19, 2026. These shares were bought at weighted average prices near $14 per share, bringing the tota

Tone
Positive 87/100
Event
Deals and strategy
Published
21 May 2026 01:11
Source
Stock Titan